A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Aggressive fibromatosis (AF, also known as desmoid tumor) is a fibroproliferative neoplasm
that typically arises in the abdomen but can develop at other anatomic sites, most commonly
in the extremities. These tumors have a relatively high local failure rate after primary
treatment using surgery and/or radiotherapy, and although rarely giving rise to distant
metastases, can be multifocal and, therefore, not surgically resectable. Moreover, tumor may
recur adjacent to the site of surgical resection, underscoring the limitations of surgery in
the palliative setting. Therefore, effective medical therapies for AF are needed to maintain
quality of life and prolong survival.The goal of the current study was to better define the
activity of imatinib in the treatment of AF and to determine the molecular basis for
response/nonresponse